Antisense Oligonucleotide (aso)

AHB-137

Manufacturers: AusperBio Therapeutics, Inc., Ausper Biopharma Co., Ltd.

AusperBio's lead investigational unconjugated antisense oligonucleotide (ASO) therapy for chronic hepatitis B (CHB).

Generate AI report

Overview

AusperBio's lead investigational unconjugated antisense oligonucleotide (ASO) therapy for chronic hepatitis B (CHB).

Mechanism of Action

Suppresses hepatitis B surface antigen (HBsAg) production, inhibits viral DNA replication, and promotes immune reactivation, with the goal of achieving a functional cure for chronic hepatitis B (CHB).

Indications

chronic hepatitis B (CHB)

Associated Conditions

1 associated conditions

chronic hepatitis B

Drug Type

antisense oligonucleotide (ASO)

Drugs